DSpace Repository

Laboratory-scale development of an over-the-counter famotidine formulation

Show simple item record

dc.contributor.author Olivier TG en
dc.date.accessioned 2016-09-22T07:17:26Z
dc.date.available 2016-09-22T07:17:26Z
dc.date.created 1996 en
dc.date.submitted 1997 en
dc.identifier.uri http://hdl.handle.net/20.500.11892/11342
dc.description.abstract The laboratoryscale development of an over-the-counter (O.T.C.) 10mg famotidine tablet is described. A literature review and drug-excipient compatibilty studies conducted at Potchefstroorn University for Christian Higher Education (P.U. for C.H.E.) represented the initial preformulation development stage. Physicochemical properties of famotidine pertinent to the formulation of a stable and bioavailable dosage form were elucidated : poor aqueous solubility (Budavari, 1989:617); poor lipophylicity (Islam & Narurkar, 1993:686); photosensitivity (McEvoy, 1995:2029); susceptibility to gastric degradation (G"uvener & Ates (1988:142); and interactions between famotidine and Kollidon, Primojel, Crospovidone, Emdex, Emcompress, lactose, sorbitol or stearic acid as reported by Tndrayanto et al. (1994:911) and/or determined by P.U. for C.H.E. The performance of five direct compression excipients viz. Zeparox spraydried lactose, Sorbitol Instant EG, Avicel pH 102 (microcrystalline cellulose), Emdex (dextrates, NV hydrate) and Emoompress (dibasic calcium phosphate dihydrate), in a tablet containing 10mg of famotidine and 1% of magnesium stearate , as lubricant, was subsequently evaluated. The influence of the diluents on selected physical properties of the powder blend and of the tablets was assessed. The direct compression excipients which performed most favourably were then selected and three model formulations were derived, with the addition of Explotab (sodium starch glycolate), as disintegrant, to enhance bioavailability. The first formulation comprised 10mg of famotidine, 8mg of Explotab, 180mg of Zeparox spray-dried lactose and 2mg of magnesium stearate per tablet. The second formulation contained 10mg of famotidine, 4mg of Explotab, 40mg of Avicel, 144mg of Emcompress and 2mg of magnesium stearate per tablet; while, the third included 10mg of famotidine, 2mg of Explotab, 166mg of Avicel and 2mg of magnesium stearate. These formulations were produced on a laboratory scale, using a Manesty F3 single punch tablet press, and were subjected to three months preliminary accelerated stability testing in polypropylene securitainers. Conditions of 40 degrees C plus minus 2 degrees C and 75% plus minus 5% relative humidity were maintained in a Gallenkamp environmental chamber. The second formulation failed accelerated stability testing; while, the first and third were found to be acceptable. The first formulation, however, demonstrated a reduction in famotidine assay and slight brown discolouration over the three months test period. The third formulation is therefore recommended. Further investigations suggested in the development of alternative 0.T.C. formulations include enteric coating to eliminate gastric degradation (G"uvener & Ates, 1988:142) and the use of melt extrusion technology (Gr"unhagen & M"uller, 1995:167) to improve biovailability and/or reduce production costs. en
dc.language English en
dc.subject Medical sciences: Pharmacology and therapeutics en
dc.subject General en
dc.title Laboratory-scale development of an over-the-counter famotidine formulation en
dc.type Masters degree en
dc.description.degree MPharm en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record